Detalles de la búsqueda
1.
Pamiparib in combination with tislelizumab in patients with advanced solid tumours: results from the dose-escalation stage of a multicentre, open-label, phase 1a/b trial.
Lancet Oncol
; 20(9): 1306-1315, 2019 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-31378459
2.
Results from AMBER, a randomized phase 2 study of bevacizumab and bortezomib versus bortezomib in relapsed or refractory multiple myeloma.
Cancer
; 119(2): 339-47, 2013 Jan 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-22811009
3.
Multinational Study of the Efficacy and Safety of Humanized Anti-HER2 Monoclonal Antibody in Women Who Have HER2-Overexpressing Metastatic Breast Cancer That Has Progressed After Chemotherapy for Metastatic Disease.
J Clin Oncol
; 41(8): 1501-1510, 2023 03 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-36881998
4.
Praluzatamab Ravtansine, a CD166-Targeting Antibody-Drug Conjugate, in Patients with Advanced Solid Tumors: An Open-Label Phase I/II Trial.
Clin Cancer Res
; 28(10): 2020-2029, 2022 05 13.
Artículo
en Inglés
| MEDLINE | ID: mdl-35165101
5.
Phase IA/IB study of single-agent tislelizumab, an investigational anti-PD-1 antibody, in solid tumors.
J Immunother Cancer
; 8(1)2020 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-32540858
6.
Results From the Phase III Randomized Trial of Onartuzumab Plus Erlotinib Versus Erlotinib in Previously Treated Stage IIIB or IV Non-Small-Cell Lung Cancer: METLung.
J Clin Oncol
; 35(4): 412-420, 2017 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-27937096
7.
Cardiac dysfunction in the trastuzumab clinical trials experience.
J Clin Oncol
; 20(5): 1215-21, 2002 Mar 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-11870163
8.
Hormone receptor status does not affect the clinical benefit of trastuzumab therapy for patients with metastatic breast cancer.
Clin Breast Cancer
; 6(3): 247-52, 2005 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-16137436
9.
Safety of Onartuzumab in Patients with Solid Tumors: Experience to Date from the Onartuzumab Clinical Trial Program.
PLoS One
; 10(10): e0139679, 2015.
Artículo
en Inglés
| MEDLINE | ID: mdl-26445503
10.
Effect of cardiac dysfunction on treatment outcomes in women receiving trastuzumab for HER2-overexpressing metastatic breast cancer.
Clin Breast Cancer
; 5(4): 293-8, 2004 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-15507176
11.
Independent adjudication of symptomatic heart failure with the use of doxorubicin and cyclophosphamide followed by trastuzumab adjuvant therapy: a combined review of cardiac data from the National Surgical Adjuvant breast and Bowel Project B-31 and the North Central Cancer Treatment Group N9831 clinical trials.
J Clin Oncol
; 28(21): 3416-21, 2010 Jul 20.
Artículo
en Inglés
| MEDLINE | ID: mdl-20530275
12.
Clinical activity of gemcitabine plus pertuzumab in platinum-resistant ovarian cancer, fallopian tube cancer, or primary peritoneal cancer.
J Clin Oncol
; 28(7): 1215-23, 2010 Mar 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-19901115
13.
Cost-effectiveness analysis of trastuzumab in the adjuvant setting for treatment of HER2-positive breast cancer.
Cancer
; 110(3): 489-98, 2007 Aug 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-17592827
14.
Reporting of adverse event data in hematopoietic stem cell transplantation clinical trials involving investigational new drugs or devices: a report from the William Guy Forbeck Foundation 2001 focus meeting on clinical trials in hematopoietic stem cell transplantation.
Biol Blood Marrow Transplant
; 8(6): 295-302, 2002.
Artículo
en Inglés
| MEDLINE | ID: mdl-12108915
Resultados
1 -
14
de 14
1
Próxima >
>>